Gero Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$17M
- Investors
-
5
Gero General Information
Description
Operator of a preclinical-stage biotechnology company intended to create therapeutics against the root causes of age-related and other chronic diseases. The company uses AI to create disease phenotypes in real-world human data and identify diseases with shared biology, enabling medical practitioners to extend a healthy lifespan and delay age-related health issues.
Contact Information
Website
www.gero.aiCorporate Office
- 133 Cecil Street
- Suite 14-01 Keck Seng Tower
- Singapore, Singapore 069535
- Singapore
Corporate Office
- 133 Cecil Street
- Suite 14-01 Keck Seng Tower
- Singapore, Singapore 069535
- Singapore
Gero Timeline
Gero Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 16-Jul-2025 | $17M | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series A) | 18-Oct-2023 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 15-Jan-2018 | $2.2M | Completed | Startup | ||
| 1. Early Stage VC (Series A) | 08-May-2020 | $2.2M | $2.2M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Gero Patents
Gero Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4291239-A2 | Compounds, compositions and methods for treating age-related diseases and conditions | Pending | 10-Feb-2021 | ||
| EP-4291239-A4 | Compounds, compositions and methods for treating age-related diseases and conditions | Pending | 10-Feb-2021 | ||
| WO-2022173333-A2 | Compounds, compositions and methods for treating age-related diseases and conditions | Inactive | 10-Feb-2021 | ||
| WO-2022173334-A2 | Methods, compositions and compounds for treating age-related diseases and conditions | Inactive | 10-Feb-2021 | ||
| US-20230190748-A1 | Compositions for treatment of aged diseases | Inactive | 27-Mar-2020 | A61K31/517 |
Gero Signals
Gero Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Melnichek Investments | Venture Capital | Minority | ||
| VitaDAO | Venture Capital | Minority | ||
| Bulba Ventures | Venture Capital | Minority | ||
| FinTech Innovation Lab | Accelerator/Incubator | Minority |
Gero FAQs
-
When was Gero founded?
Gero was founded in 2018.
-
Where is Gero headquartered?
Gero is headquartered in Singapore, Singapore.
-
What is the size of Gero?
Gero has 20 total employees.
-
What industry is Gero in?
Gero’s primary industry is Drug Discovery.
-
Is Gero a private or public company?
Gero is a Private company.
-
What is Gero’s current revenue?
The current revenue for Gero is .
-
How much funding has Gero raised over time?
Gero has raised $25.2M.
-
Who are Gero’s investors?
, Melnichek Investments, VitaDAO, Bulba Ventures, and FinTech Innovation Lab have invested in Gero.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process